Your browser doesn't support javascript.
SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals.
Coyle, Peter V; Chemaitelly, Hiam; Ben Hadj Kacem, Mohamed Ali; Abdulla Al Molawi, Naema Hassan; El Kahlout, Reham Awni; Gilliani, Imtiaz; Younes, Nourah; Al Anssari, Ghada Ali A A; Al Kanaani, Zaina; Al Khal, Abdullatif; Al Kuwari, Einas; Butt, Adeel A; Jeremijenko, Andrew; Kaleeckal, Anvar Hassan; Latif, Ali Nizar; Shaik, Riyazuddin Mohammad; Abdul Rahim, Hanan F; Nasrallah, Gheyath K; Yassine, Hadi M; Al Kuwari, Mohamed Ghaith; Al Romaihi, Hamad Eid; Al-Thani, Mohamed H; Bertollini, Roberto; Abu-Raddad, Laith J.
  • Coyle PV; Hamad Medical Corporation, Doha, P.O. Box 3050, Qatar.
  • Chemaitelly H; Biomedical Research Center, Qatar University, Doha, P.O. Box 2713, Qatar.
  • Ben Hadj Kacem MA; Wellcome-Wolfson Institute for Experimental Medicine, Queens University, Belfast, BT7 1NN United Kingdom.
  • Abdulla Al Molawi NH; Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, P.O. Box 24144, Doha, Qatar.
  • El Kahlout RA; World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, Doha, P.O. Box 24144, Qatar.
  • Gilliani I; Hamad Medical Corporation, Doha, P.O. Box 3050, Qatar.
  • Younes N; Hamad Medical Corporation, Doha, P.O. Box 3050, Qatar.
  • Al Anssari GAAA; Hamad Medical Corporation, Doha, P.O. Box 3050, Qatar.
  • Al Kanaani Z; Hamad Medical Corporation, Doha, P.O. Box 3050, Qatar.
  • Al Khal A; Hamad Medical Corporation, Doha, P.O. Box 3050, Qatar.
  • Al Kuwari E; Hamad Medical Corporation, Doha, P.O. Box 3050, Qatar.
  • Butt AA; Hamad Medical Corporation, Doha, P.O. Box 3050, Qatar.
  • Jeremijenko A; Hamad Medical Corporation, Doha, P.O. Box 3050, Qatar.
  • Kaleeckal AH; Hamad Medical Corporation, Doha, P.O. Box 3050, Qatar.
  • Latif AN; Hamad Medical Corporation, Doha, P.O. Box 3050, Qatar.
  • Shaik RM; Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, NY 10065, USA.
  • Abdul Rahim HF; Hamad Medical Corporation, Doha, P.O. Box 3050, Qatar.
  • Nasrallah GK; Hamad Medical Corporation, Doha, P.O. Box 3050, Qatar.
  • Yassine HM; Hamad Medical Corporation, Doha, P.O. Box 3050, Qatar.
  • Al Kuwari MG; Hamad Medical Corporation, Doha, P.O. Box 3050, Qatar.
  • Al Romaihi HE; College of Health Sciences, QU Health, Qatar University, Doha, P.O. Box 2713, Qatar.
  • Al-Thani MH; Biomedical Research Center, Qatar University, Doha, P.O. Box 2713, Qatar.
  • Bertollini R; Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha, P.O. Box 2713, Qatar.
  • Abu-Raddad LJ; Biomedical Research Center, Qatar University, Doha, P.O. Box 2713, Qatar.
iScience ; 24(6): 102646, 2021 Jun 25.
Article in English | MEDLINE | ID: covidwho-1240402
ABSTRACT
The study objective was to the assess level of detectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in the urban population of Qatar. Antibody testing was performed on residual blood specimens for 112,941 individuals (∼10% of Qatar's urban population) attending for routine/other clinical care between May 12 and September 9, 2020. Seropositivity was 13.3% (95% confidence interval [CI] = 13.1-13.6%) and was independently associated with sex, age, nationality, clinical care encounter type, and testing date. Median optical density (antibody titer) among antibody-positive persons was 27.0 (range = 1.0-150.0), with higher values associated with age, nationality, clinical care encounter type, and testing date. Seropositivity by nationality was positively correlated with the likelihood of having higher antibody titers (Pearson correlation coefficient = 0.85; 95% CI = 0.47-0.96). Less than two in every 10 individuals in Qatar's urban population had detectable antibodies against SARS-CoV-2, suggesting this population is still far from herd immunity and at risk of subsequent infection waves. Higher antibody titer appears to be a biomarker of repeated exposures to the infection.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Language: English Journal: IScience Year: 2021 Document Type: Article Affiliation country: J.isci.2021.102646

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Language: English Journal: IScience Year: 2021 Document Type: Article Affiliation country: J.isci.2021.102646